OPKO Health (NASDAQ:OPK) Upgraded at StockNews.com

StockNews.com upgraded shares of OPKO Health (NASDAQ:OPK) from a sell rating to a hold rating in a report published on Monday morning.

Several other research firms have also recently weighed in on OPK. Barrington Research reissued an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Monday.

OPKO Health Price Performance

Shares of OPK opened at $1.94 on Monday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -10.21 and a beta of 1.63. OPKO Health has a twelve month low of $0.86 and a twelve month high of $2.04. The company has a 50 day moving average of $1.56 and a 200-day moving average of $1.55. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, equities research analysts forecast that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 67,434 shares of the business’s stock in a transaction on Friday, February 28th. The stock was acquired at an average price of $1.71 per share, with a total value of $115,312.14. Following the acquisition, the chief executive officer now directly owns 213,301,448 shares of the company’s stock, valued at $364,745,476.08. This trade represents a 0.03 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders bought 1,389,971 shares of company stock valued at $2,124,442. 47.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. Rubric Capital Management LP lifted its holdings in OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of OPKO Health by 143.6% during the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after buying an additional 1,502,342 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of OPKO Health during the fourth quarter worth $2,082,000. Finally, Norges Bank acquired a new stake in shares of OPKO Health during the fourth quarter worth $1,657,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.